The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 study of anti–immunoglobulin-like transcript 3 (ILT3) monoclonal antibody MK-0482 + pembrolizumab + gemcitabine + nab-paclitaxel (Gem/Nab-P) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).
 
Talia Golan
No Relationships to Disclose
 
Jonathan Cohen
Honoraria - AstraZeneca; Medison; Roche
Patents, Royalties, Other Intellectual Property - provisional patent application filed
Travel, Accommodations, Expenses - Medison
 
Mark Voskoboynik
Honoraria - Merck Sharp & Dohme
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme
Research Funding - Alpine Immune Sciences (Inst); Altria (Inst); Antengene (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Hengrui Pharmaceutical (Inst); Hinova Pharmaceuticals (Inst); Merck Sharp & Dohme (Inst); Virocure (Inst)
 
Martin Gutierrez
Stock and Other Ownership Interests - Cota Healthcare
Consulting or Advisory Role - Celularity; Guardant Health; Sanofi
Speakers' Bureau - BMS; Merck
Research Funding - Acerta Pharma (Inst); Adlai Nortye (Inst); Arcus Biosciences (Inst); Array BioPharma (Inst); Bayer (Inst); Bellicum Pharmaceuticals (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Checkpoint Therapeutics (Inst); Compass Therapeutics (Inst); Constellation Pharmaceuticals (Inst); Cullinan Oncology (Inst); Cyteir (Inst); Daiichi Sankyo Company (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Georgetown Univ. (Inst); GlaxoSmithKline (Inst); GSB Pharma (Inst); Hackensack Meridian Health (Inst); Imugene (Inst); Incyte (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Johnson & Johnson (Inst); KSQ Therapeutics (Inst); MedImmune (Inst); Memorial Sloan-Kettering Cancer Center (Inst); Merck (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Moderna Therapeutics (Inst); NextCure (Inst); NextCure (Inst); Nimbus Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Rapa Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silenseed (Inst); Silenseed (Inst); Synlogic (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Vedanta Biosciences (Inst); VelosBio (Inst); Verastem (Inst); Vincerx Pharma (Inst)
 
John J. Park
No Relationships to Disclose
 
Monica Valente
Consulting or Advisory Role - Novartis
 
Daniel John Renouf
Honoraria - Bayer; Roche
Consulting or Advisory Role - Bayer; Roche; Viatris
Research Funding - Bayer; Roche (Inst)
 
Qi Liu
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Mackenzie Edmondson
Employment - Merck
Travel, Accommodations, Expenses - Merck
 
Nicole Myer
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Kishan J. Kapadia
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Mei Chen
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Iván Victoria
No Relationships to Disclose